<HTML>
<HEAD>
<TITLE>         Form 8-k DNA Patent
</TITLE>
</HEAD>
<BODY>
<PRE>
                                                  SECURITIES AND EXCHANGE COMMISSION
                                                        WASHINGTON, D. C. 20549

                                                               FORM 8-K

---------------------------------------------------------------------------------------------------------------------------------------


                         CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                                                            Date of Report
                                                           December 21, 2001


                                                      Commission File No. 0-19131




                                                              MedImmune, Inc.
                                             (Exact name of registrant as specified in its charter)


                                       Delaware                          52-1555759
                           (State or other jurisdiction of             (I.R.S. Employer
                           incorporation or organization)              Identification No.)



                                           35 West Watkins Mill Road, Gaithersburg, MD 20878
                                          (Address of principal executive offices) (Zip Code)



                                   Registrant's telephone number, including area code (301) 417-0770



<PAGE>


ITEM 5.  OTHER EVENTS

The Company issued the following press release on December 21, 2001.


                                  MEDIMMUNE HAS HELD LICENSE TO GENENTECH ANTIBODY PATENT SINCE 1997

Gaithersburg, MD, December 21, 2001 -- On December 18, 2001, Genentech, Inc. (NYSE: DNA) announced that it had been granted a patent
relating to certain methods and compositions used to produce antibodies by recombinant DNA technology. This patent had been filed by
Genentech with a priority date of 1983. Today, a number of biotechnology companies, including MedImmune (Nasdaq: MEDI), utilize
methods of recombinant DNA technology in the production of their antibody-based products. In anticipation of any potential impact
the issuance of this patent could have, four years ago, MedImmune obtained a license to Genentech's antibody production patent for
MedImmune's antibody-based product Synagis(R)(palivizumab).

MedImmune is in the process of evaluating whether any valid claim of Genentech's patent, as recently issued, covers production of
Synagis. If so, MedImmune would pay royalties to Genentech on U.S. net sales of Synagis commencing December 18, 2001. MedImmune
anticipates that incremental Synagis royalties to Genentech, if any, would not change its prior financial guidance issued on
December 3, 2001. MedImmune is also evaluating whether any of its other antibody-based product candidates, if and when approved for
marketing by the U.S. Food and Drug Administration, could require a license under the Genentech patent. There can be no assurance
that if such a license were required and available, it would be available on terms acceptable to MedImmune.

Synagis(R)(palivizumab) is marketed for the prevention of serious lower respiratory tract disease caused by respiratory syncytial
virus in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere from October through May (see
full prescribing information at www.medimmune.com).

MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in
Frederick, Maryland and Nijmegen, the Netherlands.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and
uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in
MedImmune's and Aviron's filings with the SEC. MedImmune and Aviron have confirmed that the granting of the Genentech patent does
not affect the merger agreement that they entered into on December 2, 2001.
MedImmune and Aviron are developing products for potential future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were
received, such products would ultimately achieve commercial success. There can be no assurance that MedImmune's exchange offer for
Aviron shares or the merger will close or that Aviron will be integrated successfully or without unanticipated costs.

We urge Aviron stockholders and other investors to read the registration statement on Form S-4, Schedule TO, preliminary prospectus,
supplements, final prospectus and other exchange offer documents which have been filed or will be filed by MedImmune with the
Securities and Exchange Commission and the related solicitation/recommendation statement filed by Aviron with the SEC. These
documents contain important information which should be read carefully before any decision is made with respect to the offer.
Documents filed with the SEC are available for free at the SEC's website at www.sec.gov. Documents are also available for free from
MacKenzie Partners, Inc., 800-322-2885.



                                                      SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.



                                                      MEDIMMUNE, INC.
                                                      (Registrant)



                                                      /s/: Gregory S. Patrick
Date: December 21, 2001                               Gregory S. Patrick
                                                      Senior Vice President and Chief Financial Officer

</PRE>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "f8kdnapatent.htm", "description": "FORM 8-K DNA PATENT", "secsgml_size_bytes": 6314}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "1820766"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
Form 8-k DNA Patent
SECURITIES AND EXCHANGE COMMISSION
                                                        WASHINGTON, D. C. 20549

                                                               FORM 8-K

---------------------------------------------------------------------------------------------------------------------------------------

                         CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                                                            Date of Report
                                                           December 21, 2001

                                                      Commission File No. 0-19131

                                                              MedImmune, Inc.
                                             (Exact name of registrant as specified in its charter)

                                       Delaware                          52-1555759
                           (State or other jurisdiction of             (I.R.S. Employer
                           incorporation or organization)              Identification No.)

                                           35 West Watkins Mill Road, Gaithersburg, MD 20878
                                          (Address of principal executive offices) (Zip Code)

                                   Registrant's telephone number, including area code (301) 417-0770
ITEM 5.  OTHER EVENTS

The Company issued the following press release on December 21, 2001.

                                  MEDIMMUNE HAS HELD LICENSE TO GENENTECH ANTIBODY PATENT SINCE 1997

Gaithersburg, MD, December 21, 2001 -- On December 18, 2001, Genentech, Inc. (NYSE: DNA) announced that it had been granted a patent
relating to certain methods and compositions used to produce antibodies by recombinant DNA technology. This patent had been filed by
Genentech with a priority date of 1983. Today, a number of biotechnology companies, including MedImmune (Nasdaq: MEDI), utilize
methods of recombinant DNA technology in the production of their antibody-based products. In anticipation of any potential impact
the issuance of this patent could have, four years ago, MedImmune obtained a license to Genentech's antibody production patent for
MedImmune's antibody-based product Synagis(R)(palivizumab).

MedImmune is in the process of evaluating whether any valid claim of Genentech's patent, as recently issued, covers production of
Synagis. If so, MedImmune would pay royalties to Genentech on U.S. net sales of Synagis commencing December 18, 2001. MedImmune
anticipates that incremental Synagis royalties to Genentech, if any, would not change its prior financial guidance issued on
December 3, 2001. MedImmune is also evaluating whether any of its other antibody-based product candidates, if and when approved for
marketing by the U.S. Food and Drug Administration, could require a license under the Genentech patent. There can be no assurance
that if such a license were required and available, it would be available on terms acceptable to MedImmune.

Synagis(R)(palivizumab) is marketed for the prevention of serious lower respiratory tract disease caused by respiratory syncytial
virus in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere from October through May (see
full prescribing information at www.medimmune.com).

MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as
infectious disease, immune regulation and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in
Frederick, Maryland and Nijmegen, the Netherlands.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and
uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ
materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in
MedImmune's and Aviron's filings with the SEC. MedImmune and Aviron have confirmed that the granting of the Genentech patent does
not affect the merger agreement that they entered into on December 2, 2001.
MedImmune and Aviron are developing products for potential future marketing. There can be no assurance that such development efforts
will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were
received, such products would ultimately achieve commercial success. There can be no assurance that MedImmune's exchange offer for
Aviron shares or the merger will close or that Aviron will be integrated successfully or without unanticipated costs.

We urge Aviron stockholders and other investors to read the registration statement on Form S-4, Schedule TO, preliminary prospectus,
supplements, final prospectus and other exchange offer documents which have been filed or will be filed by MedImmune with the
Securities and Exchange Commission and the related solicitation/recommendation statement filed by Aviron with the SEC. These
documents contain important information which should be read carefully before any decision is made with respect to the offer.
Documents filed with the SEC are available for free at the SEC's website at www.sec.gov. Documents are also available for free from
MacKenzie Partners, Inc., 800-322-2885.

                                                      SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.

                                                      MEDIMMUNE, INC.
                                                      (Registrant)

                                                      /s/: Gregory S. Patrick
Date: December 21, 2001                               Gregory S. Patrick
                                                      Senior Vice President and Chief Financial Officer